PatentsGlobal
Regentis Biomaterials Secures Japanese Patent to Expand GelrinC Manufacturing and IP Portfolio in Global Cartilage Repair Market
New patent allowance in Japan complements recent U.S. grant, reinforcing proprietary solvent-free production process and ready-to-use formulation for GelrinC amid advancing commer…
Regentis Biomaterials (NYSE American: RGNT) has obtained a Japanese patent allowance that strengthens its intellectual property protection for the organic solvent-free manufacturing process and ready-to-use liquid formulation behind GelrinC, its cell-free hydrogel for knee cartilage repair. This milestone follows a re…